Podcasts · Science

Talking Points

TCTMD

214 episodes

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

Episodes page 4 of 5

  1. Episode 111: The PARALLAX Trial

    · 9:25

    Burkert Pieske and C. Michael Gibson discuss sacubitril/valsartan versus individualized RAAS blockade in HFpEF.

  2. Episode 110: The HOME-PE Trial

    · 9:26

    Pierre-Marie Roy and C. Michael Gibson discuss hospitalization or outpatient management of PE.

  3. Episode 109: The EAST-AFNET 4 Trial

    · 14 min

    Paulus Kirchhof and C. Michael Gibson discuss early rhythm control therapy in patients with atrial fibrillation.

  4. Episode 108: The BPLTTC Trial

    · 5:03

    Kazem Rahimi and C. Michael Gibson discuss BP-lowering for prevention of cardiovascular events.

  5. Episode 107: LoDoCo2 Low-Dose Colchicine in Coronary Disease

    · 7:28

    Dr. Jan Cornel and Dr. C. Michael Gibson Discuss: LoDoCo2 Low-Dose Colchicine in Coronary Disease.

  6. Episode 106: TCT Connect 2020

    · 29 min

    C. Michael Gibson, Ajay Kirtane, Mamas Mamas, and Roxana Mehran talk TCT 2020.

  7. Episode 105: POPULAR TAVI

    · 6:04

    C. Michael Gibson and Jorn Brouwer discuss aspirin with or without clopidogrel after transcatheter aortic valve replacement.

  8. Episode 104: EMPEROR Reduced

    · 17 min

    C. Michael GIbson and Milton Packer Discuss empagliflozin in heart failure with reduced ejection fraction.

  9. Episode 103: New ESC NSTEMI Guidelines

    · 9:42

    C. Michael Gibson and Roxana Mehran discuss new ESC NSTEMI guidelines and more

  10. Episode 102: Innovation in Mitral Valve Repair

    · 2:58

    C. Michael Gibson and Steven Goldberg discuss REDUCE-FMR and sham-controlled trials in MV repair.

  11. Episode 101: PARTNER 2A: 5-Year Outcomes

    · 2:54

    C. Michael Gibson and Vinod Thourani discuss 5-year outcomes in this randomized trial of TAVR vs SAVR in intermediate-risk patients.

  12. Episode 100: COAPT Cost-effectiveness Analysis Plus Health-Status Outcomes in PARTNER 3

    · 5:22

    Suzanne Baron and C. Michael Gibson discuss important new details from these two structural heart disease trials.

  13. Episode 99: EVOLVE Short DAPT: 3-Month DAPT in Patients

    · 2:13

    C. Michael Gibson and Ajay Kirtane review the results of this single-arm stent study.

  14. Episode 98: #WomenAs1: The Battle for Gender Equality

    · 6:14

    Roxana Mehran brings C. Michael Gibson up to speed on a campaign to promote talent in medicine by offering professional opportunities to female physicians.

  15. Episode 97: TWILIGHT: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin

    · 4:15

    Usman Baber, who led this thrombogenicity substudy, walks C. Michael Gibson through the key findings.

  16. Episode 96: IVUS-XPL: Intravascular Ultrasound-Guided vs. Angiography-Guided PCI

    · 5:09

    C. Michael Gibson and Myeong-Ki Hong discuss 5-year outcomes in this randomized trial.

  17. Episode 95: FORZA: Randomized Trial of Fractional Flow Reserve

    · 5:52

    What are the respective values of FFR and OCT in guiding revascularization? C. Michael Gibson gets a primer from Francesco Burzotta.

  18. Episode 94: Wearables - The Future Is Now

    · 6:04

    C. Michael Gibson connects with Sameer Mehta and Francisco Fernandez to hear how new tech is poised to disrupt medical care.

  19. Episode 93: Onyx ONE

    · 7:00

    C. Michael Gibson learns about the Onyx ONE trial from Stephan Windecker.

  20. Episode 92: TWILIGHT: Ticagrelor Monotherapy vs Ticagrelor Plus Aspirin

    · 5:33

    C. Michael Gibson reviews the randomized TWILIGHT trial results with Roxana Mehran.

  21. Episode 91: Propensity Score-Matched Analysis

    · 4:12

    Maurizio Taramasso walks C. Michael Gibson through randomized data focused on tricuspid valve disease.

  22. Episode 90: MODEL U-SES: 3-Month DAPT in Patients at High Bleeding Risk

    · 3:37

    C. Michael Gibson hears from Ken Kozuma about the single-arm MODEL U-SES study.

  23. Episode 89: STS Registry: Mitral Valve Surgery Institutional Volume-Outcome Relationship in the US

    · 8:14

    Vinay Badhwar discusses new data from the STS Registry addressing volume/outcome relationships for mitral valve surgery.

  24. Episode 86: REMEDIAL III: Urine Flow Rate-Guided vs LVEDP-Guided Hydration

    · 4:15

    C. Michael Gibsons sits down with Carlo Briguori to discuss the REMEDIAL III trial results.

  25. Episode 85: REDUCE-FMR: Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation

    · 6:16

    Samir Kapadia, Horst Sievert, and C. Michael Gibson discuss this randomized sham-controlled trial of the Carillon device.

  26. Episode 84: A Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor in STEMI

    · 7:20

    C. Michael Gibson and Dean Kereiakes discuss the first human use of RUC-4, designed for STEMI point-of-care treatment.

  27. Episode 83: The Medically Ill Patients in AUGUSTUS

    · 3:07

    C. Michael Gibson discusses the AUGUSTUS trial with Renato Lopes.

  28. Episode 82: EXCEL: 5-Year Outcomes

    · 9:26

    C. Michael Gibson speaks with Gregg Stone about EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease.

  29. Episode 81: COAPT 3-Year Outcomes

    · 4:17

    C. Michael Gibson speaks with Michael Mack about the COAPT Trial 3-year outcomes and results.

  30. Episode 80: PARTNER 3 Low-Risk Computed Tomography Substudy

    · 5:47

    C. Michael Gibson speaks with Raj Makkar about PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

  31. Episode 79: LEVANT: 5-Year Outcomes From Three Randomized Trials

    · 4:08

    C. Michael Gibson speaks with Kenneth Ouriel about LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

  32. Episode 78: REDUCE-FMR: A Sham-Controlled Randomized Trial

    · 2:59

    C. Michael Gibson sits down with Horst Sievert to learn more about the REDUCE-FMR trial.

  33. Episode 77: PREPARE-CALC: High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation

    · 4:26

    C. Michael Gibson gets the details on PREPARE-CALC from Gert Richardt.

  34. Episode 76: Annapoorna Kini: Clinician, Researcher, Educator, and App Developer

    · 6:35

    C. Michael Gibson learns more about Annapoorna Kini's work and why the field needs female role models.

  35. Episode 75: CorMicA: A Randomized Trial of Invasive Coronary Function Testing

    · 8:14

    C. Michael Gibson and Tom Ford discuss the potential for finding and treating patients with ANOCA.

  36. Episode 74: Quality of Life in the COAPT Study

    · 8:36

    C. Michael Gibson and David Cohen discuss adding years to life and adding life to years with the MitraClip.

  37. Episode 73: COMPARE ABSORB

    · 2:10

    C. Michael Gibson and Pieter Smits walk us through the COMPARE ABSORB trial.

  38. Episode 72: NEOPRO: Nonrandomized Comparison of Two Transcatheter Heart Valves

    · 5:44

    C. Michael Gibson and Azeem Latib take a closer look at some next-gen TAVR devices.

  39. Episode 71: ULTIMATE: A Randomized Trial of Intravascular Ultrasound Guidance

    · 4:58

    C. Michael Gibson and Junjie Zhang discuss ULTIMATE: A Randomized Trial of Intravascular Ultrasound Guidance of Coronary Drug-Eluting Stent Implantation in an All-Comers Patient Population.

  40. Episode 70: FAST-FFR: Accuracy of Fractional Flow Reserve Derived From Coronary Angiography

    · 5:10

    C. Michael Gibson and William Fearon talk FFR-CT.

  41. Episode 69: SOLVE-TAVI: A 2x2 Randomized Trial of Transcather Aortic Valve Implantation

    · 7:07

    C. Michael Gibson and Holger Thiele take a deep dive into a head-to-head trial of TAVR devices that also considered general versus local anesthesia.

  42. Episode 68: TALENT: A Randomized Trial

    · 6:36

    C. Michael Gibson talks with Patrick Serruys about, TALENT: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population."

  43. Episode 67: RESET: Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents

    · 4:14

    C. Michael Gibson and Hiroki Shiomi look at long-term outcomes from RESET.

  44. Episode 66: PORTICO I: One-Year Outcomes

    · 3:31

    C. Michael Gibson and Lars Sondergaard discuss 1-year outcomes in the PORTICO I trial.

  45. Episode 65: SECURE-PCI: Impact of Timing of Atorvastatin Loading Dose

    · 4:58

    Does timing of an atorvastatin loading dose make a difference in PCI for ACS? C. Michael Gibson and Renato Lopes discuss.

  46. Episode 64: Building a New Backbone Upon Which to Randomize Patients: PERT Registry

    · 11 min

    C. Michael Gibson, Kenneth Rosenfield, and Robert Lookstein discuss the way forward for PERT.

  47. Episode 63: TRIVALVE: Evaluation of Edge-to-Edge Valve Repair

    · 3:57

    C. Michael Gibson and Jörg Hausleiter discuss the TRIVALVE trial.

  48. Episode 62: BIONYX: A Randomized Trial

    · 5:38

    C. Michael Gibson and Clemens von Birgelen discuss the BIONYX randomized trial.

  49. Episode 61: ReCre8: A Randomized Trial Evaluating a Polymer-Free Coronary Drug-Eluting Stent

    · 3:30

    C. Michael Gibson and Pieter Stella discuss ReCre8, which evaluated a polymer-free DES in an all-comers population.

  50. Episode 60: What Do You Get When You Combine Twitter and a Textbook? Tweetbook

    · 3:44

    What do you get when you combine Twitter and a textbook? C. Michael Gibson talks with Michael Savage and David Fischman.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.